UAE says Covid-19 drug Sotrovimab resulted in ‘100% prevention of death’

The use of the anti-viral medicine Sotrovimab in treating mild to moderate Covid-19 cases among high-risk patients in the UAE has resulted in “100 per cent prevention of death among recipients and 99 per cent prevention of admission to ICU”, officials have said.

The drug was administered to 6,175 patients with Covid-19 in Abu Dhabi between June 30 and July 13. About 52 per cent of the patients were aged 50 or above, and almost all recipients had multiple comorbidities including obesity, cancer, cardiovascular disease and diabetes.

The medication also resulted in the full recovery of 97 per cent of the recipients within 14 days, the UAE’s Ministry of Health and Prevention (MoHAP), in collaboration with the Department of Health – Abu Dhabi and Dubai Health Authority revealed.

مجموعة من الأطباء في شركة أبوظبي للخدمات الصحية "صحة" يتحدثون عن فعالية عقار سوتروفيماب لعلاج الحالات الخطرة المصابة بـ #كوفيد_19. pic.twitter.com/HRy0enHaiz

— مكتب أبوظبي الإعلامي (@admediaoffice) July 17, 2021

The Ministry of Health and Prevention has approved the use of Sotrovimab, which is produced by global biopharmaceutical company GlaxoSmithKline (GSK), after conducting local evaluation. It has also been approved for emergency use by the US Food and Drug Administration.

Sotrovimab is a monoclonal antibody treatment delivered through intravenous therapy, and can be used to treat adults and children above the age of 12 who meet certain criteria and are at risk of progressing to a severe Covid-19 condition, as per protocols that have been developed by the National Scientific Committee.

The UAE was one of the first countries in the world to receive a shipment of Sotrovimab in mid-June, following an agreement between the Department of Health – Abu Dhabi, Rafed, a leading group purchasing organisation, GSK and Etihad Cargo.

Read: Abu Dhabi becomes first location to receive new Covid-19 medication